Numis Securities reiterated their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report published on Wednesday. Numis Securities currently has a GBX 1,300 ($17.50) price target on the stock.

Other equities research analysts have also issued research reports about the stock. Stifel Nicolaus dropped their price target on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.77) to GBX 1,000 ($13.46) and set a hold rating on the stock in a research note on Thursday, November 9th. Goldman Sachs Group lowered shares of Hikma Pharmaceuticals to a neutral rating and dropped their price target for the company from GBX 2,600 ($34.99) to GBX 1,310 ($17.63) in a research note on Tuesday, August 22nd. Peel Hunt restated a hold rating and issued a GBX 1,390 ($18.71) price target on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 15th. Citigroup restated a neutral rating and issued a GBX 1,350 ($18.17) price target on shares of Hikma Pharmaceuticals in a research note on Thursday, August 24th. Finally, dropped their price target on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.27) to GBX 865 ($11.64) and set a reduce rating on the stock in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. Hikma Pharmaceuticals currently has an average rating of Hold and an average target price of GBX 1,188.90 ($16.00).

Shares of Hikma Pharmaceuticals (LON HIK) opened at GBX 1,143 ($15.38) on Wednesday. Hikma Pharmaceuticals has a 12 month low of GBX 906.50 ($12.20) and a 12 month high of GBX 2,346 ($31.57). The company has a market cap of $2,730.00 and a P/E ratio of 2,198.08.

TRADEMARK VIOLATION WARNING: “Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Numis Securities” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/hikma-pharmaceuticals-hik-buy-rating-reiterated-at-numis-securities/1780892.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.